Introduction {#S1}
============

Human and animal gastrointestinal (GI) tracts are ecosystems colonized with trillions of diverse microbes and have a level of complexity comparable to that of an organ system ([@B19]). The host gut and its microbiome have coevolved as a physiological community ([@B1]). Gut microbes have important roles in host health, from nutrient absorption to modulating the functions of the host immune system and the gut-brain interactions ([@B5]; [@B14]; [@B27]). While the exact mechanisms and pathways involved in the complex interplay between hosts and the gut microbiota still remain largely unknown, gut microbiota dysbiosis has been associated with various "modern" human health problems, such as inflammatory bowel diseases (IBDs), type 2 diabetes, colorectal cancer in adults ([@B13]), *Clostridium difficile* infection (CDI), necrotizing enterocolitis, asthma in children ([@B21]; [@B31]), mental health disorders ([@B35]), and even affecting the efficacy of drugs ([@B44]; [@B15]; [@B34]). In the past few years, microbiota transplant (MT) has emerged as a popular strategy to replenish healthy gut microbiota and treat diseases ([@B20]). For example, fecal microbiota transplant (FMT) is found effective in treating CDI and eliminating *C. difficile* from the intestinal tract of infected patients ([@B24]). Seeding maternal vaginal microbiota to infant mouth and skin of Cesarean section (C-section) delivered babies has also been practiced with the intention to help these babies develop normal gut microbiota ([@B10]). However, emerging evidences also illustrated that public health risk factors, such as viruses or bacterial pathogens, were introduced to patients' microbiota through MT ([@B16]; [@B40]). Despite FMT being presented as a potential mechanism to reduce gut resistome, the data from [@B24] in fact clearly demonstrated that FMT introduced new antibiotic resistant (AR) genes to the patients.

The rapid surge of AR pathogens has become a top global public health threat ([@B49]; [@B22]; [@B47]). However, effective mitigation only becomes possible when our scope and strategies are no longer restricted to limiting the applications of antibiotics ([@B11]; [@B45]; [@B46]; [@B30]). For instance, once AR commensal bacteria and even probiotics and fermentation starter cultures associated with ready-to-consume foods were identified as the key avenue impacting host gut resistome through food intake, successful mitigation of the largest foodborne AR gene pool was achieved in just 4 years (2006--2010), owing to the quick removal of the problematic starter cultures and probiotics from the product lines ([@B25]). Thus, redefining probiotics and mandatory safety screening of microbes intended for beneficial applications across human health as well as food animal and agricultural productions have also become stressing needs in order to mitigate the spread AR in the ecosystem.

The host gastrointestinal tract system has pivotal roles in AR ecology independent from antibiotic exposure. Without conventional food exposure, antibiotic resistance genes (ARGs), and resistant bacteria were still found quickly surged in infant fecal microbiota within days after birth without antibiotic treatment, most likely due to the oral/nasal exposure to mother's microbiota during natural birth and breastfeeding ([@B50]). ARGs and resistant bacteria are also found abundant in feces of animals from antibiotic-free production system ([@B6]; [@B51]). [@B49] further illustrated that 5-day antibiotic treatment only led to the rapid surge of the targeted ARGs in fecal microbiota of mice previously seeded with the corresponding ARG-containing bacteria, but not in placebo mice without seeding, regardless of the 5-day antibiotic treatment. These data clearly illustrated that, besides the application of antibiotic itself, introducing exogenous AR bacteria to the host GI tract system is an overlooked, but key risk factor leading to the rapid surge of AR bacteria in the gut and fecal microbiota. Unfortunately, the public health risk has already turned into a reality. According to the safety alert by the U.S. Food and Drug Administration (FDA) issued on June 13, 2019, two immunocompromised adults contracted invasive infections from FMT that contained extended-spectrum β-lactamase (ESBL)-producing *Escherichia coli* ([@B41]; [@B7]). One of these patients died. Therefore, improving knowledge as well as communicating and further limiting the public health consequences of MT have become critical.

In recent years, high-throughput sequencing (HTS)-based metagenomics have revolutionized our understanding of host microbiome, especially the complexity and diversity of the gut microbiota ([@B39]). The availabilities of the metagenomics analysis tools ([@B3]) as well as the abundance of gut microbiome sequence data from various studies have made investigations with new scope possible. By retrospectively reassessing cohorts of metagenomics datasets, this study revealed the dynamics of resistomes in recipients associated with MT, and the potential public health risks associated with related practices.

Materials and Methods {#S2}
=====================

Sample Information {#S2.SS1}
------------------

Recently published shotgun metagenomes from stool samples of infants, patients with Crohn's Disease (CD), vaginal samples from mothers before delivery, as well as transplanted piglets were targeted to assess the impact of MT on AR dissemination and colonization in the gut of recipients. Raw metagenomics data sets were filtered according to the following criteria for further analyses: (1) the samples should be related to MT; (2) the shotgun metagenomics data have been previously published and are available; and (3) the samples provided sufficient background information (such as donors and recipients).

Metagenomics data of a total of 44 samples resulting from 3 independently published studies were used in this study. Samples included 6 maternal vaginal samples, and stools of 16 infants, 10 CD patients, 4 donors, and 8 humanized germ-free piglets ([@B13]; [@B43]; [@B8]).

Metagenomics Data Retrieval and Preprocessing {#S2.SS2}
---------------------------------------------

The Sequence Read Archive database (SRA) was retrieved from the repository NCBI_SRA (BioProject Accession: [PRJNA484151](PRJNA484151), [Table 1](#T1){ref-type="table"}; PRJNA321058, [Table 2](#T2){ref-type="table"}; and PRJNA352475, [Table 3](#T3){ref-type="table"}) in.sra format. The retrieved files were converted to.fastq using SRA Toolkit 2.9.6 for Ubuntu Linux^[1](#footnote1){ref-type="fn"}^. [Tables 1](#T1){ref-type="table"}--[3](#T3){ref-type="table"} summarized the sequence information. A series of independent data-"dump" utilities were included in the SRA Toolkit, which were used to convert SRA data to different file formats. For instance, Fastq-dump allowed for conversion of SRA data into fastq or fasta format in the current study. The FASTP tool (v0.19.5) was used for quality control (QC) and removal of low quality sequences with default parameters before annotation and analysis of the generated raw reads in each metagenomics dataset ([@B4]). The parameters of filtering data by FASTP tool including: phred quality of reads ≤ Q15 were unqualified and removed; 40% of bases in reads are allowed to be unqualified; sequences with five or more non-ATCG characters were also removed; reads shorter than required length of 80 were discarded.

###### 

The sequence accession numbers in the list of Bioproject [PRJNA484151](PRJNA484151).

  Run          BioSample      AvgSpotLen   Collection_date   Experiment   Isolation_source                 Library name   MBases   MBytes   Organism           Sample name
  ------------ -------------- ------------ ----------------- ------------ -------------------------------- -------------- -------- -------- ------------------ -------------
  SRR7642163   SAMN09762371   474          1-June-15         SRX4505614   Homo sapiens-Amish infant2       HR6            554      319      Human metagenome   HR6
  SRR7642164   SAMN09762379   466          1-Jun-15          SRX4505613   Homo sapiens-Non-Amish infant5   HU18           997      568      Human metagenome   HU18
  SRR7642165   SAMN09762378   466          1-Jun-15          SRX4505612   Homo sapiens-Non-Amish infant4   HU17           1019     599      Human metagenome   HU17
  SRR7642166   SAMN09762370   468          1-Jun-15          SRX4505611   Homo sapiens-Amish infant1       HR5            904      544      Human metagenome   HR5
  SRR7642167   SAMN09762381   467          1-Aug-16          SRX4505610   Sus scrofa domesticus2           PUC2           759      439      Pig metagenome     PUC2
  SRR7642168   SAMN09762380   467          1-Aug-16          SRX4505609   Sus scrofa domesticus1           PUC1           915      574      Pig metagenome     PUC1
  SRR7642169   SAMN09762383   474          1-Aug-16          SRX4505608   Sus scrofa domesticus4           PUC4           599      357      Pig metagenome     PUC4
  SRR7642170   SAMN09762382   463          1-Aug-16          SRX4505607   Sus scrofa domesticus3           PUC3           808      461      Pig metagenome     PUC3
  SRR7642171   SAMN09762385   465          1-Dec-15          SRX4505606   Sus scrofa domesticus6           PRC2           775      449      Pig metagenome     PRC2
  SRR7642172   SAMN09762384   467          1-Dec-15          SRX4505605   Sus scrofa domesticus5           PRC1           740      441      Pig metagenome     PRC1
  SRR7642173   SAMN09762387   468          1-Dec-15          SRX4505604   Sus scrofa domesticus8           PRC4           798      490      Pig metagenome     PRC4
  SRR7642174   SAMN09762386   464          1-Dec-15          SRX4505603   Sus scrofa domesticus7           PRC3           843      503      Pig metagenome     PRC3
  SRR7642175   SAMN09762376   463          1-Jun-15          SRX4505602   Homo sapiens-Non-Amish infant2   HU12           901      514      Human metagenome   HU12
  SRR7642176   SAMN09762373   451          1-Jun-15          SRX4505601   Homo sapiens-Amish infant5       HR8            761      442      Human metagenome   HR8
  SRR7642177   SAMN09762377   467          1-Jun-15          SRX4505600   Homo sapiens-Non-Amish infant3   HU16           812      484      Human metagenome   HU16
  SRR7642178   SAMN09762375   470          1-Jun-15          SRX4505599   Homo sapiens-Non-Amish infant1   HU11           690      404      Human metagenome   HU11
  SRR7642179   SAMN09762372   472          1-Jun-15          SRX4505598   Homo sapiens-Amish infant3       HR7            712      399      Human metagenome   HR7
  SRR7642180   SAMN09762374   474          1-Jun-15          SRX4505597   Homo sapiens-Amish infant4       HR10           675      385      Human metagenome   HR10

###### 

The sequence accession numbers in the list of Bioproject [PRJNA321058](PRJNA321058).

  Run          BioSample      AvgSpotLen   Experiment   Gastroinstest_disord   Host_subject_ID   Library name   MBases   MBytes   Sample name   Time_point
  ------------ -------------- ------------ ------------ ---------------------- ----------------- -------------- -------- -------- ------------- -------------------
  SRR3582147   SAMN05065750   197          SRX1797372   Crohn's disease        R1009             G85458         2073     1394     G85458        pre-FMT
  SRR3582154   SAMN05065730   198          SRX1797379   Crohn's disease        R1007             G85435         3298     2224     G85435        pre-FMT
  SRR3582173   SAMN05065774   197          SRX1797398   Crohn's disease        R1022             G85485         3183     2287     G85485        pre-FMT
  SRR3582175   SAMN05065776   198          SRX1797400   Crohn's disease        R1021             G85487         2925     1989     G85487        pre-FMT
  SRR3582180   SAMN05065733   198          SRX1797405   Crohn's disease        R1005             G85438         3398     2294     G85438        pre-FMT
  SRR3582138   SAMN05065742   198          SRX1797363   Crohn's disease        R1005             G85450         2170     1463     G85450        4 weeks after FMT
  SRR3582139   SAMN05065743   198          SRX1797364   Crohn's disease        R1007             G85451         3172     2129     G85451        4 weeks after FMT
  SRR3582148   SAMN05065751   199          SRX1797373   Crohn's disease        R1009             G85459         5387     3677     G85459        4 weeks after FMT
  SRR3582170   SAMN05065771   199          SRX1797395   Crohn's disease        R1022             G85482         2948     2010     G85482        4 weeks after FMT
  SRR3582172   SAMN05065773   198          SRX1797397   Crohn's disease        R1021             G85484         2149     1437     G85484        4 weeks after FMT
  SRR3582142   SAMN05065746   198          SRX1797367   NA                     D9004             G85454         4279     2888     G85454        NA
  SRR3582134   SAMN05065738   199          SRX1797359   NA                     D9001             G85444         4639     3132     G85444        NA
  SRR3582179   SAMN05065779   199          SRX1797404   NA                     D9002             G90607         9475     3633     G90607        NA
  SRR3582158   SAMN05065760   199          SRX1797383   NA                     D9005             G85470         5901     3980     G85470        NA

###### 

The sequence accession numbers in the list of Bioproject [PRJNA352475](PRJNA352475).

  Run          BioSample      AvgSpotLen   Couple_Id   Donor    Experiment   Infant_age       Isolation_source    Library name   MBases   MBytes   Sample name
  ------------ -------------- ------------ ----------- -------- ------------ ---------------- ------------------- -------------- -------- -------- -------------------------
  SRR5273969   SAMN06350145   181          10031       Mother   SRX2577952   Not applicable   Vaginal introitus   2527_t0        2359     1085     CA_C10031MS2527VA_t0M15
  SRR5273966   SAMN06350148   197          10031       Infant   SRX2577949   3 days           Stool               2537_t3        2243     1054     CA_C10031IS2537FE_t3M15
  SRR5274002   SAMN06350112   192          10023       Mother   SRX2577985   Not applicable   Vaginal introitus   2387_t0        1251     568      CA_C10023MS2387VA_t0M15
  SRR5274004   SAMN06350110   183          10023       Infant   SRX2577987   3 days           Stool               2393_t2        4984     2246     CA_C10023IS2393FE_t2M15
  SRR5273911   SAMN06350203   195          10043       Mother   SRX2577894   Not applicable   Vaginal introitus   2743_t0        786      352      CA_C10043MS2743VA_t0M15
  SRR5273915   SAMN06350199   195          10043       Infant   SRX2577898   3 days           Stool               2749_t2        5267     2373     CA_C10043IS2749FE_t2M16
  SRR5273991   SAMN06350123   174          10024       Mother   SRX2577974   Not applicable   Vaginal introitus   2405_t0        198      87       CA_C10024MS2405VA_t0M15
  SRR5273995   SAMN06350119   181          10024       Infant   SRX2577978   3 days           Stool               2411_t2        5175     2339     CA_C10024IS2411FE_t2M15
  SRR5273932   SAMN06350182   188          10039       Mother   SRX2577915   Not applicable   Vaginal introitus   2671_t0        134      60       CA_C10039MS2671VA_t0M15
  SRR5273929   SAMN06350185   194          10039       Infant   SRX2577912   3 days           Stool               2677_t2        3873     1791     CA_C10039IS2677FE_t2M16
  SRR5274056   SAMN06350058   182          10007       Mother   SRX2578039   Not applicable   Vaginal introitus   2099_t0        167      73       CA_C10007MS2099VA_t0M15
  SRR5274053   SAMN06350061   179          10007       Infant   SRX2578036   3 days           Stool               2105_t2        2885     1310     CA_C10007IS2105FE_t2M15

Relative Abundance of ARGs {#S2.SS3}
--------------------------

To characterize the profiles of ARGs, a direct annotation service was employed by uploading the post-QC processing paired-end metagenome reads to the DeepARG web service^[2](#footnote2){ref-type="fn"}^. The DeepARG web service contains a fully automated raw metagenomic analysis pipeline for ARG annotation with a high degree of confidence ([@B2]). This tool is based on the deepARG algorithm and the deepARG-DB, which currently comprises 30 antibiotic categories, 2149 groups, and 14,933 non-redundant reference sequences (2203 from CARD, 10,602 from UNIPROT, and 2128 from ARDB), and has been under continuous inspection ([@B2]). The results of ARG profiles are normalized to the 16S rRNA gene abundance in the samples automatically by the platform, based on the deepARG algorithm and the deepARG-DB, as described at the DeepARG website^[3](#footnote3){ref-type="fn"}^.

Statistical Analysis {#S2.SS4}
--------------------

The datasets of the three studies were analyzed independently. The relative abundance of ARGs were processed in R designed by R Core Team (version 3.5.2) using the package ggplot2 (version 3.1.0). To distinguish the differences in diversity and abundance of the types of ARGs, boxplots of each detected ARG class with significance levels were visualized using packages ggpubr (version 0.2.4) in R software. The ARG subtypes of the pairing samples to compare with Venny 2.1^[4](#footnote4){ref-type="fn"}^ to generate the Venn diagram.

Results and Discussion {#S3}
======================

Rural and Urban Infant Fecal Microbiota Transplant {#S3.SS1}
--------------------------------------------------

The relative abundance of ARGs varied from 0.43 to 1.37 in the rural infant stools, and 0.26 to 1.56 in urban infant stools ([Figures 1A,B](#F1){ref-type="fig"}). These results illustrated that the abundances of ARGs in the rural and urban infant stools were quite similar. In total, 22 classes of ARGs were found in all samples. Multidrug resistance genes were the most abundant ARGs in the rural and urban infant stools, followed by those encoding resistance to tetracycline, β-lactam, and macrolide-lincosamide-streptogramin (MLS). The high abundance of these four most dominant AR types is consistent with previous reports of fecal samples from different countries ([@B48]; [@B12]). The differences between the abundance of each ARG type in the two types of samples were also analyzed. Among the 22 ARG types, the abundance of each ARG type exhibited no significant difference between the two types of samples.

![Abundance of ARGs in host gut microbiota. **(A)** Fecal microbiota of rural infants and transplanted piglets. **(B)** Fecal microbiota of urban infants and transplanted piglets. **(C)** Comparison of fecal microbiota of rural infants and transplanted piglets. **(D)** Comparison of fecal microbiota of urban infants and transplanted piglets. HR, rural infant; HU, urban infant; PRC, transplanted piglets from rural infant; PUC, transplanted piglets from urban infant; a, average value.](fmicb-11-00932-g001){#F1}

Clearly, the profiles of human gut microbiome are influenced by many factors associated with rural or urban lifestyle ([@B23]). Previously, several studies have compared rural and urban gut microbiota, and proposed that rural communities can serve as a source of preferred healthy microbiota. For instance, [@B42] suggested that transplantation using fecal microbiota from rural communities may be an effective way to restore healthy gut microbiota in the human population of industrialized countries. However, data from this study revealed similar abundance of ARGs in fecal microbiota of rural Amish and urban infants. Although the initial intention of [@B8] who generated the metagenomics data used in this study was to illustrate the potential of FMT in enhancing host immune function, our fecal resistome results clearly demonstrated that fecal microbiota of rural (Amish) community had comparable ARGs to those of urban subjects, and therefore no less health risk.

[Figures 1A,B](#F1){ref-type="fig"} also illustrated that the relative abundance of ARGs varied from 5.86 to 13.27 in the rural fecal transplanted piglets, and 2.19 to 6.41 in piglets transplanted with urban fecal microbiota. In total, 23 classes of ARGs were found in all samples. The genes resistant to multidrug, unclassified, MLS, aminoglycoside, and fluoroquinolone were the five most dominant types in piglets transplanted with rural fecal microbiota. However, the most abundant ARGs in piglets transplanted with urban fecal microbiota were those encoding resistance to multidrug, tetracycline, MLS, unclassified, and aminoglycoside. The data suggested that even when the two groups of donors had comparable AR gene prevalence and abundance, the fecal microbiota profiles and resistomes of the transplanted pigs corresponding to rural, and urban donors varied significantly. Instead of being safer and healthier source of microbiota, as shown in [Figure 1](#F1){ref-type="fig"}, the relative abundance of aminoglycoside, β-lactam, fluoroquinolone, nitroimidazole, and peptide resistance genes in piglets transplanted with rural fecal microbiota were actually considerably higher than those in piglets transplanted with urban fecal microbiota.

The impact of the resistomes of donors on that of the recipients was further illustrated by the relative abundance of ARGs in samples of rural infants and the transplanted piglets ([Figure 1A](#F1){ref-type="fig"}). The abundance of ARGs in piglets transplanted with rural fecal microbiota was on average 13.1 times higher than that in the rural infant donor stools. Similarly, the abundance of ARGs in piglets transplanted with urban fecal microbiota was on average 4.7 times greater than those in the corresponding urban infant stool ([Figure 1B](#F1){ref-type="fig"}). Among the 23 ARG types, the abundance of aminoglycoside, β-lactam, fluoroquinolone, MLS, and multidrug resistance genes in gut microbiota of the transplanted piglets were significantly higher than those in the infant donor stools ([Figures 1C,D](#F1){ref-type="fig"}). The significant amplification of the ARGs in germ-free recipient pigs suggested that the impact of the microbial inoculation is especially prominent in recipients with naïve gut microbiota. These results in germ-free piglet models were consistent with previous studies concluding that the gut microbiota of infants had higher abundance of ARGs compared to those of their mothers, even in the absence of antibiotic exposure ([@B33]).

In total, 141 and 173 ARG subtypes were detected in 5 rural infants and 4 piglets transplanted with rural fecal microbiota, respectively ([Figure 4A](#F4){ref-type="fig"}). Out of the 193 subtypes of ARGs detected in all samples, a total of 52 subtypes were only detected in piglets transplanted with rural fecal microbiota, accounting for 26.9% of total number of ARG subtypes detected. Similarly, the ARG subtypes detected in 5 urban infants and 4 transplanted piglets were 141 and 170, respectively. The unique ARG subtypes in 4 transplanted piglets were 42, contributing to 23.0% of the total ARG subtype numbers detected.

Previous studies have shown that the pre-existing gut microbiota significantly affected the outcomes of MT ([@B36]). But the rapid surge of ARGs in the gut microbiota of naïve pig recipients after MT, especially the difference between the recipients and the original donors, were still astonishing and need special attention. This finding suggests that even without antibiotic exposure, seeding of AR bacteria to naïve GI tract systems may have been a critical contributor to the rapid enrichment of certain AR bacteria in human and animal feces, including the emergence of ARGs previously below detection limit in the donor microbiome, further impacting the environmental AR gene pool. Moreover, AR bacteria from rural infant donors led to higher proliferation of ARGs in fecal microbiota of the recipients than those of urban infants in this case. Whether this impact is due to the long-term fitness of such bacteria in hosts, despite rural populations rarely exposed to modern drugs, is yet to be elucidated.

Resistome of Maternal Vaginal Microbiota and the Potential Impact on Infants {#S3.SS2}
----------------------------------------------------------------------------

To access the potential health risks of vaginal seeding beyond the possible transmission of pathogens and viruses ([@B16]; [@B38]), the resistomes of six maternal vaginas were examined in this study and illustrated in [Figure 2](#F2){ref-type="fig"}. The relative abundance of ARGs varied from 0.08 to 1.14 in vaginal microbiota. In total, 16 classes of ARGs were found in all samples ([Figure 2A](#F2){ref-type="fig"}). The resistance genes to tetracycline, multidrug, MLS, unclassified, and β-lactam were the five most dominant types in maternal vaginas. The comparisons of ARG abundance between maternal vagina and the corresponding infant stool samples were shown in [Figures 2A,B](#F2){ref-type="fig"}. The abundance of aminoglycoside, fluoroquinolone, and multidrug resistance genes in infant stools were significantly higher than those in the corresponding maternal vaginas. Moreover, out of the 24 classes of ARGs, the abundance of fosfomycin, nucleoside, and diaminopyrimidine could only be found in infant stool samples, which were below the detection limit in maternal vaginal microbiota. The data are consistent with the findings from the transplanted pigs.

![Abundance of ARGs in host gut microbiota. **(A)** Vaginal microbiota of expectant mother and fecal microbiota of her infant. **(B)** Comparison of vaginal microbiota of expectant mother and fecal microbiota of her infant. M, mother; I, infant; a, average value. The number is Library Name in the list of Bioproject [PRJNA352475](PRJNA352475).](fmicb-11-00932-g002){#F2}

The significant enrichment and expanding of the ARG profiles in infants, in agreement with the results from germ-free recipient pigs, also suggested that the impact of the initial microbial inoculation is especially prominent in recipients with naïve gut microbiota. The data indicated the potential risk of transmitting ARGs through exposure to vaginal or fecal microbiota, which is further in agreement with previous conclusions that bacterial communities acquired by vaginally delivered infants resembled their own mother's vaginal microbiota ([@B9]), and the early development of ARGs in the infant gut microbiota is likely impacted by exposure to maternal and environmental microbes ([@B50]). It is worth noting that while the germ-free piglets shared the same delivery approach, sanitized living environment, and heat-treated dairy feed, human infants were exposed to more environmental and feeding variables, through environmental contact, breastfeeding, etc.

Shifts in ARG Abundance in Crohn's Disease Patients Following Fecal Microbiota Transplant {#S3.SS3}
-----------------------------------------------------------------------------------------

As shown in [Figure 3A](#F3){ref-type="fig"}, the abundance of ARGs varied from 0.66 to 4.36 and 0.80 to 2.09 in fecal microbiota of CD patients pre- FMT and 4 weeks post- FMT, respectively. The average abundance of ARGs in patients pre-FMT and 4 weeks post-FMT were quite similar. However, the total ARG abundance after FMT increased in 3 out of 5 patients, remained about the same in one patient, and decreased in another patient ([Figure 3A](#F3){ref-type="fig"}). Meanwhile, the top five most abundant ARGs in patients of both pre-FMT as well as 4 weeks post-FMT were multidrug, tetracycline, MLS, β-lactam, and aminoglycoside ([Figure 3B](#F3){ref-type="fig"}). Among the 22 ARG types, the abundance of each ARG type exhibited no significant difference between the two types of samples ([Figure 3B](#F3){ref-type="fig"}).

![Abundance of ARGs in host gut microbiota. **(A)** Fecal microbiota of donors, Crohn' Disease (CD) patients pre-and post-FMT. **(B)** Comparison of fecal microbiota of CD patients pre-and post-FMT. D, donor; P, pre-FMT; A, post-FMT; a, average value. The number is host_subject_ID in the list of Bioproject [PRJNA321058](PRJNA321058).](fmicb-11-00932-g003){#F3}

![Venn diagram showing the number of shared and unique ARGs. **(A)** Fecal microbiota of infants and transplanted piglets. **(B)** Fecal microbiota of Crohn's Disease (CD) patients pre-and post-FMT. Resistome of fecal microbiota of Crohn's Disease patients pre- and post-FMT. HR, rural infant; HU, urban infant; PRC, transplanted piglets from rural infant; PUC, transplanted piglets from urban infant; P, pre-FMT; A, post-FMT. The number is host_subject_ID in the list of Bioproject [PRJNA321058](PRJNA321058).](fmicb-11-00932-g004){#F4}

The number of detected ARG subtypes in stool samples of patient recipients varied from 103 to 151 in pre-FMT and 4 weeks post-FMT ([Figure 4B](#F4){ref-type="fig"}). Out of the total ARG subtypes detected in all samples, the unique ARG subtypes varied from 11 to 63 in stool samples of recipients 4 weeks post-FMT, accounting for 9.9--42.3% of the total ARG subtypes detected. The stool sample of recipient A1021 (Accession number: [SRR3582172](SRR3582172)) was an exception, without unique ARG subtypes being detected.

Despite several reports proposed that FMT can be effective in eradicating pathogenic AR bacteria and ARGs, data also showed that several clinically significant ARGs emerged in recipient gut microbiota immediately after FMT ([@B18]; [@B30]; [@B24]). Our findings are in agreement with previous reports showing that the pre-existing gut microbiota significantly affected the outcomes of MT ([@B36]) and even *C. difficile* infection could still reoccur after FMT ([@B30]). In this study, the increase, retention, and decrease of abundance of ARGs were 60, 20, and 20%, respectively, in patients 4 weeks after FMT. It is expected that the responses to FMT were related to the existing gut microbiota of the recipients, which might vary among subjects.

Conclusion and Perspective {#S4}
==========================

The retro-assessments of the metagenomics data from 3 different studies clearly demonstrated that ARGs are prevalent across multiple body habitats, i.e., guts, vagina, etc., as well as in rural and urban populations, and MTs can spread risk factors including AR bacteria to the recipients. The rapid surge of ARGs in transplanted piglets and infants that far exceeded the abundances found in the donor microbiota revealed the potential public health risks associated with MTs, especially to subjects with naïve gut microbiota. This finding also confirmed another overlooked key cause of the escalated swelling of ARGs in the next generation of hosts---with history of no exposure to antibiotic but surely to AR bacteria via natural birth, breastfeeding, conventional eating, and waste contamination, etc.

While replenishing the gut with healthy microbiota is a good intention, the term "healthy microbiota" is far more complicated. The FDA clearly discouraged MT but supported the uses of defined strains in 2016. Expanding cocktails of defined strains likely can be a practical approach leading to more productive outcomes.

Fecal microbiota transplant had varied impact on the gut microbiota of adult CD patients, reflecting the impact of recipients' existing microbiota on the newcomers. Oral drugs, drugs excreted through the liver/gut, and especially oral administration of antibiotics massively destroy existing gut microbiota ([@B37]; [@B49]; [@B26]; [@B17]; [@B28]; [@B29]; [@B32]), not only selecting resistant bacteria and leading to gut microbiota dysbiosis, but also creating a new naïve gut environment that potentially facilitates the surge of pathogens and ARGs in patients due to the lack of effective defense from the existing gut microbiota.

In conclusion, MT is still a practice with significant public health risk. It may potentially be used as the last option to treat severe diseases instead of a common practice intended to improve host health. Proper strategies to retain and improve gut health should rely on minimizing unnecessary damages to gut microbiota, such as massive AR and gut microbiota dysbiosis due to oral administration of antibiotics and taking gut impacting drugs. While eliminating risk factors including AR bacteria and opportunistic pathogens directly from donor fecal microbiota is still hard to achieve, developing microbial cocktails with defined organisms and functions has become a stressing need should microbiota transplantation become necessary.
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